Close

Macrocure Ltd. (MCUR) Finishes Enrollment for Phase 3 Trial of CureXcell

September 2, 2014 11:29 AM EDT Send to a Friend
Macrocure Ltd. (Nasdaq: MCUR), a clinical-stage biotechnology company focused on developing a novel therapeutic platform to address chronic and hard-to-heal ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login